Preliminary testing indicated that the product did not contain any of the stated active ingredient, hydrochlorothiazide, and glibenclamide had instead been identified.
1242
经与所述制造商核实，已确认该产品为伪造。
Verification with the stated manufacturer confirmed this product to be falsified.
1243
当地卫生行政部门已被告知这一事件。
The localhealth authorities were informed of this incident.
1244
表1：世卫组织2019年第6期医疗产品警报所涉伪造的（50毫克装）氢氯噻嗪产品详情
Table 1: Details of the falsified product hydrochlorothiazide 50mg, subject of WHO medical product alert N°6/2019
1245
该产品以每个含有1000片的塑料容器呈现。
This product is presented in plastic containers of 1000 tablets each.
1246
标签语言为法文和英文。
The label is in French and Englishlanguages.
1247
经进一步开展实验室确认分析，已确定以上详述产品：
Further confirmatory laboratory analysis has established that the above-mentioned product:
1248
不含任何应有的氢氯噻嗪活性成分，但
does not contain any of the expected active ingredient, hydrochlorothiazide, but
1249
含有约5毫克的格列本脲。
contains approximately 5mg of glibenclamide.
1250
这对正在用氢氯噻嗪治疗高血压的患者带来了风险。
This represents a risk for patients who are taking hydrochlorothiazide for the treatment of hypertension.